BREAKING NEWS
Source: COVID-19-Cardiovacular Deaths  Dec 30, 2021  6 months ago
Finally! An American Study That Confirms What We Have Been Saying All This Time…..COVID-19 Is Contributing To Excess Deaths From Heart Issues!
Finally! An American Study That Confirms What We Have Been Saying All This Time…..COVID-19 Is Contributing To Excess Deaths From Heart Issues!
Source: COVID-19-Cardiovacular Deaths  Dec 30, 2021  6 months ago
COVID-19-Cardiovacular Deaths: A new study by researchers from Oregon Health & Science University, Cleveland Clinic Lerner Research Institute and the Chicago Medical School at Rosalind Franklin University have in a new study found that either symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes and has causal effect on all-cause mortality in a late post-COVID-19 period.



The study findings confirm what Thailand Medical News has been telling all this while, there are many people simply dropping dead due to sudden heart events and others that are hospitalized for such heart events but eventually still dying, all due to COVID-19!

Have A Heart And Do Not Ignore This Appeal For Help! Please help support this website and also our research and community initiatives by making a donation. Your help saves lives directly and indirectly. Thank You.
https://www.thailandmedical.news/p/sponsorship

 
It is not just myocarditis that is affecting the those that have recovered from either asymptomatic or symptomatic COVID-19 but a variety of issues are also affecting the heart.
 
Many people can testify that in the last two years of incidences involving either their loved ones, relatives, friends, work colleagues or people that they knew who were otherwise seemingly healthy, simply dropping dead from cardiovascular events.
 
Yet many health authorities and doctors are refusing to correlate these with COVID-19!
 
It is even alarming that many asymptomatic people do not even know that they contracted the SARS-CoV-2 virus and are unaware that they are at a much higher risk of dying from cardiovascular issues!
 
The study was to determine absolute and relative risks of either symptomatic or asymptomatic SARS-CoV-2 infection for late cardiovascular events and all-cause mortality.
 
The COVID-19-Cardiovacular Deaths study team conducted a retrospective double-cohort study of patients with either symptomatic or asymptomatic SARS-CoV-2 infection [COVID-19(+) cohort] and its documented absence [COVID-19(-) cohort].
 
The study team drew a simple random sample of records from all Oregon Health & Science University (OHSU) Healthcare patients (N=65,585) with available COVID-19 test results, performed 03.01.2020 - 09.13.2020. Exclusion criteria were age < 18y and no established OHSU care. The primary outcome was a composite of cardiovascular morbidity and mortality. All-cause mortality was the secondary outcome.
 
The study population included 1355 patients (mean age 48.7±20.5 y; 770(57%) female, 977(72%) white non-Hispanic; 1072(79%) insured; 563(42%) with cardiovascular disease (CVD) history).
 
The study fining showed that during a median 6 months at risk, the primary composite outcome was observed in 38/319 (12%) COVID-19(+) and 65/1036 (6%) COVID-19(-) patients (p=0.001). In Cox regression adjusted for demographics, health insurance, and reason for COVID-19 testing, SARS-CoV-2 infection was associated with the risk of the primary composite outcome (HR 1.71; 95%CI 1.06-2.78; p=0.029). Inverse-probability-weighted estimation, conditioned for 31 covariates, showed that for every COVID-19(+) patient, the average time to all-cause death was 65.5 days less than when all these patients were COVID-19(-): average treatment effect on the treated -65.5 (95%CI -125.4 to -5.61) days; p=0.032.
 
The study findings concluded that either symptomatic or asymptomatic SARS-CoV-2 infection is associated with increased risk of late cardiovascular outcomes and has causal effect on all-cause mortality in a late post-COVID-19 period.
 
The study findings were published on a preprint server and are currently being peer reviewed. https://www.medrxiv.org/content/10.1101/2021.12.27.21268448v1
 
The study team found that either symptomatic or asymptomatic SARS-CoV-2 infection was associated with increased risk of late cardiovascular outcomes, occurring at least 30 days (on average 10 months) after SARSCoV-2 infection. Importantly, we demonstrated the effect of COVID-19 infection on cardiovascular events, regardless of initial presenting COVID-19 symptoms.
 
This new but important study finding highlights the importance of COVID-19 prevention and suggests that careful follow-up might be needed for any patient who experienced SARS-CoV-2 infection, either symptomatic or asymptomatic, to monitor for late cardiovascular events.
 
The next significant finding of the study was the causal effect of either symptomatic or asymptomatic SARS-CoV-2 infection on all-cause death occurring during the post-acute or late COVID-19 period.
 
There is both pathophysiological basis and clinical evidence of significant cardiovascular risk following COVID-19.
https://pubmed.ncbi.nlm.nih.gov/32170560/
 
Numerous new studies confirmed the risks of long-term cardiovascular consequences of COVID-19 while showing a wide range of an estimated disease burden.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916
 
https://pubmed.ncbi.nlm.nih.gov/34714493/
 
https://bmjopensem.bmj.com/content/bmjosem/7/4/e001164.full.pdf
 
Numerous other small cardiac magnetic resonance (CMR) case-control studies of patients who recovered from mild or moderate COVID-19 showed a high prevalence (71-78%) of CMR abnormalities.
https://jamanetwork.com/journals/jamacardiology/fullarticle/2768916
 
https://pubmed.ncbi.nlm.nih.gov/34714493/
 
But, other small (n=58) case-control studies reported relatively low (21%) prevalence of CMR abnormalities 6 months after moderate-to-severe COVID-19.
https://www.sciencedirect.com/science/article/pii/S0002870321001976
 
Moreover, a well-matched case-control (n=75) 6-month post-COVID-19 CMR study concluded that there were no differences in the left ventricular (LV) structure, function, and scar burden between cases and controls.
https://pubmed.ncbi.nlm.nih.gov/33975819/
 
Importantly, cohort studies have advantages over case-control studies as all individuals are derived from the same study population, and there is no uncertainty regarding the time of exposure preceding the outcome when establishing a cause and effect relationship.
 
This double-cohort study was the first to estimate both absolute (attributable) and relative risks of SARS-CoV-2 infection for the development of late cardiovascular outcomes.
 
The study team concluded, “As we begin to care for more survivors of COVID-19, we will need to better understand not only how to care for their acute symptoms and complications following infection, but also recognize future cardiovascular risk and mitigate such risk with appropriate screening and preventative measures.”
 
Have A Heart And Do Not Ignore This Appeal For Help! Please help support this website and also our research and community initiatives by making a donation. Your help saves lives directly and indirectly. Thank You.
https://www.thailandmedical.news/p/sponsorship

 
For the latest on COVID-19-Cardiovacular Deaths, keep on logging to Thailand Medical News.

Check out our therapeutic teas for Long COVID specifically for heart issues is a must have for all.
https://www.thailandmedical.news/news/new-therapeutic-teas-

For a limited period, we are having as special promotion for our readers.
https://www.thailandmedical.news/news/special-promotion-of-tmn-prophylactic-and-therapeutic-teas-for-the-covid-19-era-and-a-new-range-for-long-covid


 

MOST READ

Aug 13, 2020  2 years ago
Source: Supplements For COVID-19
Feb 05, 2020  2 years ago
Source : Thailand Medical news